The contribution and perspectives of proteomics to uncover ovarian cancer tumor markers

Autor(es)

De Carvalho, Vinicius Pereira ; Grassi, Mariana Lopes ; Palma, Camila de Souza ; Angotti Carrara, Helio Humberto ; Faca, Vitor Marcel ; Candido dos Reis, Francisco Jose ; Poersch, Aline ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Dept Biochem & Immunol, FMRP, Av Bandeirantes 3900, BR-14040900 Ribeirao Preto, SP - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: TRANSLATIONAL RESEARCH; v. 206, p. 71-90, APR 2019.
• Citações Web of Science: 2

Resumo

Despite all the advances in understanding the mechanisms involved in ovarian cancer (OC) development, many aspects still need to be unraveled and understood. Tumor markers (TMs) are of special interest in this disease. Some aspects of clinical management of OC might be improved by the use of validated TMs, such as differentiating subtypes, defining the most appropriate treatment, monitoring the course of the disease, or predicting clinical outcome. The Food and Drug Administration (FDA) has approved a few TMs for OC: CA125 (cancer antigen 125; monitoring), HE4 (Human epididymis protein; monitoring), ROMA (Risk Of Malignancy Algorithm; HE4+CA125; prediction of malignancy) and OVA1 (Vermillion's first-generation Multivariate Index Assay (MIA); prediction of malignancy). Proteomics can help advance the research in the field of TMs for OC. A variety of biological materials are being used in proteomic analysis, among them tumor tissues, interstitial fluids, tumor fluids, ascites, plasma, and ovarian cancer cell lines. However, the discovery and validation of new TMs for OC is still very challenging. The enormous heterogeneity of histological types of samples and the individual variability of patients (lifestyle, comorbidities, drug use, and family history) are difficult to overcome in research protocols. In this work, we sought to gather relevant information regarding TMs, OC, biological samples for proteomic analysis, as well as markers and algorithms approved by the FDA for use in clinical routine. (AU)

• Processo FAPESP: 13/08755-0 - Estudo da modulação de potenciais biomarcadores do câncer de ovário durante a progressão tumoral através da análise proteômica dirigida
• Beneficiário: Mariana Lopes Grassi
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 10/50883-8 - Estudo proteomico de fluidos intra-tumorais na identificacao de novos biomarcadores para o diagnostico precoce do cancer de ovario.
• Beneficiário: Aline Poersch
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 15/08693-0 - Estudo proteômico da translocação subcelular de proteínas relacionadas ao desenvolvimento do câncer de mama
• Beneficiário: Camila de Souza Palma
• Modalidade de apoio: Bolsas no Brasil - Doutorado